Advances in prenatal interventional treatment for fetal congenital heart disease
- VernacularTitle:胎儿先天性心脏病的产前介入治疗进展
- Author:
Luoming HU
1
,
2
;
Haiyun YUAN
1
,
2
;
Jimei CHEN
1
,
2
Author Information
1. 1. Department of Cardiothoracic Surgery, Guangdong Provincial People&rsquo
2. s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510515, P. R. China 2. Guangdong Cardiovascular Institute, Guangdong Provincial Peoples Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, P. R. China
- Publication Type:Journal Article
- Keywords:
Congenital heart disease;
prenatal interventional treatment;
fetal aortic valvuloplasty;
fetal pulmonary valvuloplasty;
fetal cardiac intervention;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(07):1022-1028
- CountryChina
- Language:Chinese
-
Abstract:
This review provides an overview of prenatal interventional treatments for fetal congenital heart disease (CHD), with a particular focus on the latest advancements in fetal aortic valvuloplasty (FAV) and fetal pulmonary valvuloplasty (FPV). FAV aims to improve left heart hemodynamics, prevent hypoplastic left heart syndrome (HLHS), and promote biventricular circulation. FPV seeks to improve the natural history of pulmonary atresia with intact ventricular septum (PA/IVS) and critical pulmonary stenosis with intact ventricular septum (CPS/IVS), alleviate right ventricular outflow tract obstruction, and promote biventricular circulation. This article discusses patient selection, technical details, risk assessment, and clinical outcomes for these procedures, highlighting the challenges in current research, including the lack of standardized patient selection criteria and long-term prognostic studies. Additionally, it emphasizes the opportunities and challenges of fetal cardiac intervention (FCI) development in China and proposes recommendations for future improvements and research directions.
